# Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

> **NCT00367315** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1684 (—)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** Lumiracoxib

## Key facts

- **NCT ID:** NCT00367315
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-02
- **Final completion:** —
- **Target enrollment:** 1684 (—)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367315, "Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00367315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*